LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article: Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy.

Ramos-Ruperez, Elena / Escudero-Vilaplana, Vicente / Ruiz-Briones, Paula / Collado-Borrell, Roberto / Villanueva-Bueno, Cristina / Revuelta-Herrero, José Luis / González-Haba, Eva / Garcia-Gonzalez, Xandra / Ibañez-Garcia, Sara / Perez-Ramirez, Sara / Zatarain-Nicolás, Eduardo / Herranz, Ana / Sanjurjo, María

Frontiers in oncology

2023  Volume 13, Page(s) 1220305

Abstract: Objective: The management of cardiotoxicity concerning the use of oral antineoplastic agents (OAAs) is a challenge for healthcare professionals. Our objective was to create a comprehensive medication management guide with dose adjustment recommendations ...

Abstract Objective: The management of cardiotoxicity concerning the use of oral antineoplastic agents (OAAs) is a challenge for healthcare professionals. Our objective was to create a comprehensive medication management guide with dose adjustment recommendations on OAAs concerning cardiotoxic and lipid metabolic adverse events (AEs) to assist healthcare professionals when prescribing OAAs.
Materials and methods: A review of the available information on all dose adjustments necessary to safely prescribe and dispense OAAs concerning cardiotoxicity was conducted. In January 2023, we identified all OAAs authorized by the European Medicines Agency (EMA). For each drug, the latest summary of product characteristics (SPC) approved by the EMA and the tertiary data source Lexicomp
Results: In all, 93 different OAAs had been approved by the EMA and were reviewed. Among them, 51.6% have recognized cardiotoxic AEs and 10.8% can cause alterations in lipid metabolism. A total of 27 (29.0%) OAAs had specific recommendations regarding QT prolongation; 88.9% were listed in the SPC and 59.3% in Lexicomp
Conclusions: More than half of the OAAs can produce cardiotoxic effects, with the most frequent being blood pressure alteration and QT interval prolongation with a non-depreciable incidence of LV dysfunction or thrombosis. Before starting the treatment, it is necessary to stratify baseline cardiovascular risk, plan a surveillance schedule, and consider referral to cardio-oncology units.
Language English
Publishing date 2023-08-25
Publishing country Switzerland
Document type Journal Article
ZDB-ID 2649216-7
ISSN 2234-943X
ISSN 2234-943X
DOI 10.3389/fonc.2023.1220305
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top